The Osteoporosis Market Outlook to 2021 - New Market Study Published


Recently published research from Datamonitor, "The Osteoporosis Market Outlook to 2021", is now available at Fast Market Research


Published on 20 March 2013


by Bill Thompson

(WireNews+Co)

Boston, MA

The seven major markets are characterized by an aging population and hence the incidence of osteoporosis will increase accordingly. The increase in patient numbers, however, will not lead to an increase in overall market value as the genericization of key bisphosphonate brands will cause heavy price erosion, leading to a negative growth trend that will continue throughout the forecast period.

Report Scope

- Pdf report containing Datamonitor's analysis and forecasts of this market to 2021.
- Forecast based on epidemiology data and primary research with 129 primary care physicians and specialists across the US, Japan, and 5EU.
- This forecast assesses the impact of generics, especially upon patent expiry of key bisphosphonate drugs such as Actonel, Boniva, and Reclast.
- Forecasts of the four new key products launching during the forecast period: Amgen's AMG-785, Radius' BA058, Pfizer's Aprela, and Merck's odanacatib.

View Full Report Details (http://www.fastmr.com/prod/546446_the_osteoporosis_market_outlook_to_2021.aspx?afid=201)

Report Hightlights

The growth in sales of newer products, such as Prolia (denosumab; Amgen) and soon-to-launch odanacatib (Merck & Co.) can only partly offset the market value decline caused by generic price erosion.

Odanacatib will become the top-grossing pipeline drug by the end of the forecast period.

Reasons to Get this Report

- Which brands will be affected by generic erosion the most; where and when will it take place?
- What is the impact of new pipeline drugs going to be and how successful can they become in a cost-constrained market?

Partial Table of Contents:

Table of Contents
Overview
Executive Summary
Datamonitor key findings
Forecast Trend Analysis
Market value will decline despite patient population growth
The osteoporosis market will see the successful introduction of two novel drug classes, causing revenue to
pick up
Bibliography
Methodology and Market Definition
Market definition for osteoporosis
Patient-based forecast methodology
Price and dose assumptions
Product launches
Patent expiries
Physician sample breakdown
Bibliography
US
Bibliography
Japan
Five Major EU Markets
Bibliography
Fosamax/Fosamax Plus D (alendronate; Merck & Co)
Forecast assumptions
Actonel/Actonel with Calcium/Atelvia (risedronate; Sanofi/Warner Chilcott)
Forecast assumptions
Bibliography
Bonviva/Boniva (ibandronate; Roche/GlaxoSmithKline)
Forecast assumptions
Bibliography
Aclasta/Reclast (zoledronic acid; Novartis)
Forecast assumptions
Bonoteo/Recalbon (minodronate; Astellas/Ono Pharma)
Forecast assumptions
Didronel (etidronate; Warner Chilcott/Pfizer/Sumitomo Pharma)
Forecast assumptions
Nerixia (neridronate; Abiogen Pharma)
Forecast assumptions
Aredia (pamidronate; Novartis)
Forecast assumptions
Protelos (strontium ranelate; Servier)
Forecast assumptions
Bibliography
Evista (raloxifene; Eli Lilly)
Forecast assumptions
Conbriza/Viviant (bazedoxifene; Pfizer/Almirall)
Forecast assumptions
Bibliography
Edirol (eldecalcitol; Chugai/Taisho)
Forecast assumptions
Forteo/Forsteo (teriparatide; Eli Lilly)
Forecast assumptions
Preotact/Preos (human parathyroid hormone; Nycomed/NPS Pharma)
Forecast assumptions
Prolia (denosumab; Amgen/GlaxoSmithKline/Daiichi Sankyo)
Forecast assumptions
Bibliography
Odanacatib (MK-0822; Merck & Co)
Forecast assumptions

View Full Table of Contents




Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget.  For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


Contacts

  •  
  • Bill Thompson
  • Fast Market Research, Inc.
  • PR Contact
  • Tel: +14134857001
  •  
Enter your email:
Enter Subject:
Enter your message:
Please enter this numbers in the fields:
 
  Click image to get a new code.
Enter code:
 

Posted 2013-03-20 06:24:00